Article Sidebar

PDF
Date Published: 14/03/2023
Online Published: 14/03/2023
Abstract Views: 114
Views PDF: 71
DOI: https://doi.org/10.52714/dthu.12.2.2023.1031
Issue
Vol. 12 No. 2 (2023): Natural Sciences Issue (Vietnamese)
Section
Natural Sciences Issue
How to Cite
Huynh, T. N. T., Nguyen, Q. T., & Bui, V. T. (2023). Studying the interaction of CID 16040294 compound with beta amyloid by docking method. Dong Thap University Journal of Science, 12(2), 44-49. https://doi.org/10.52714/dthu.12.2.2023.1031

Studying the interaction of CID 16040294 compound with beta amyloid by docking method

Thi Ngoc Thanh Huynh1, Quoc Thai Nguyen2, , Van Thang Bui3
1 IT and Lab Center, Dong Thap University, Vietnam
2 Department of Natural Sciences Teacher Education, Dong Thap University, Vietnam
3 Academic Aff airs Offi ce, Dong Thap University, Vietnam

Main Article Content

Abstract

The amyloid hypothesis admits that the Alzheimer’s disease etiology is associated with selfassembly of amyloid beta (Aβ) peptides inside the brain. The Aβ peptides are produced by proteolytic cleavage of the amyloid precursor protein (APP) by β-secretase and γ-secretase. Among these, Aβ42 is more toxic than Aβ40 and is the cause of neuronal cell death. Using docking simulation, the interaction of CID 16040294 (GVD) with Aβ42 fibrils was investigated. The results show that CID 16040294 (GVD) strongly interacts with Aβ42 fibrils, interacts best with the 2MXU fibril structure, and the non-binding interaction plays a more important role than Hydrogen bonding in the steady state of the receptor-ligand conformation. From these results, we propose that GVD compound is a potential compound to treat Alzheimer’s disease.

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Keywords

Amyloid beta, Alzheimer's disease, docking method, binding free energy

References

Aguzzi, A., & T. O'Connor. (2010). Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nat Rev Drug Discov, 9(3), 237-248.
Alzheimer’s, A. (2015). 2015 Alzheimer's disease facts and figures. Alzheimer's & dementia: the journal of the Alzheimer's Association, 11(3), 332.
Bush, A. I. (2002). Metal complexing agents as therapies for Alzheimer’s disease. Neurobiology of aging, 23(6), 1031-1038.
Colvin, M. T., Silvers, R., Ni, Q. Z., Can, T. V., Sergeyev, I., Rosay, M., ... & Griffin, R. G. (2016). Atomic Resolution Structure of Monomorphic A beta (42) Amyloid Fibrils. Journal of the American Chemical Society, 138(30): 9663-9674.
Hardy, J., & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 297(5580): 353-356.
Herrup, K. (2015). The case for rejecting the amyloid cascade hypothesis. Nature neuroscience: 794-799.
Kollman, P. A., Massova, I., Reyes, C., Kuhn, B., Huo, S., Chong, L., ... & Cheatham, T. E. (2000). Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Accounts of chemical research 33(12), 889-897.
Nasica-Labouze, J., Nguyen, P. H., Sterpone, F., Berthoumieu, O., Buchete, N. V., Cote, S., ... & Derreumaux, P. (2015). Amyloid β protein and Alzheimer’s disease: When computer simulations complement experimental studies. Chemical reviews, 115(9), 3518-3563.
Sanner, M. F. (1999). Python: a programming language for software integration and development. J Mol Graph Model, 17(1), 57-61.
Thai, N. Q., Nguyen, H. L., Linh, H. Q., & Li, M. S. (2017). Protocol for fast screening of multi-target drug candidates: Application to Alzheimer’s disease. Journal of Molecular Graphics and Modelling, 77, 121-129.
Trott, O., & Olson, A. J. (2010). AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, effi cient optimization, and multithreading. Journal of computational chemistry, 31(2), 455-461.
Viet, M. H., Chen, C. Y., Hu, C. K., Chen, Y. R., & Li, M. S. (2013). Discovery of dihydrochalcone as potential lead for Alzheimer’s disease: in silico and in vitro study. PloS one, 8(11), 79151.
Huy, P. D. Q., Yu, Y. C., Ngo, S. T., Van Thao, T., Chen, C. P., Li, M. S., & Chen, Y. C. (2013). In silico and in vitro characterization of anti-amyloidogenic activity of vitamin K3 analogues for Alzheimer's disease, Biochimica et biophysica acta, 1830(4), 2960-2969.
Viet, M. H., Siposova, K., Bednarikova, Z., Antosova, A., Nguyen, T. T., Gazova, Z., & Li, M. S. (2015). In silico and in vitro study of binding affinity of tripeptides to amyloid β fi brils: implications for Alzheimer’s disease. The Journal of Physical Chemistry B, 119(16), 5145-5155.
Wälti, M. A., Ravotti, F., Arai, H., Glabe, C. G., Wall, J. S., Böckmann, A., ... & Riek, R. (2016). Atomic-resolution structure of a disease-relevant Aβ (1-4c2) amyloid fibril. Proceedings of the National Academy of Sciences, 113(34), E4976-E4984.
Wilson, R. S., Segawa, E., Boyle, P. A., Anagnos, S. E., Hizel, L. P., & Bennett, D. A. (2012). The natural history of cognitive decline in Alzheimer's disease. Psychology and aging, 27(4), 1008.
Xiao, Y., Ma, B., McElheny, D., Parthasarathy, S., Long, F., Hoshi, M., ... & Ishii, Y. (2015). Aβ (1-42) fi bril structure illuminates self-recognition and replication of amyloid in Alzheimer's disease. Nature structural & molecular biology, 22(6), 499-505.

Most read articles by the same author(s)

1 2 > >>